(+)-JNJ-A07 是一种靶向 NS3-NS4B 相互作用的高效泛血清型登革热病毒抑制剂。(+)-JNJ-A07 对 21 株临床分离株发挥纳摩尔到皮摩尔的活性。(+)-JNJ-A07 具有良好的药代动力学特征，在小鼠感染模型中对登革热病毒感染有显著疗效。

(+)-JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+)-JNJ-A07 exerts nanomolar to picomolar activity against a panel of 21 clinical isolates. (+)-JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models [1].

(+)-JNJ-A07 has a high barrier to resistance and prevents the formation of the viral replication complex by blocking the interaction between two viral proteins (NS3 and NS4B) [1].

2135640-93-4

C28H26ClF3N2O6

578.96

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years